June 2016

New Product - Cotellic

Cotellic (cobimetinib fumarate) is an orally available inhibitor of MEK1 and MEK2 tyrosine‑threonine kinases. The mitogen‑activated protein kinase (MAPK)/extracellular signal regulated kinase (MEK) pathway is a key signaling pathway that regulates cell proliferation, cell cycle regulation, cell survival, angiogenesis, and cell migration. Cobimetinib has shown high inhibitory potency in biochemical and cell based assays, as well as anti-tumour activity in vivo in xenograft tumour models mutated for BRAF (also showed efficacy in some KRAS mutant models). Cotellic is indicated for use in combination with Zelboraf (vemurafenib) for the treatment of patients with unresectable or metastatic melanoma with BRAF V600 mutation. Cotellic is available as 20 mg tablets in packs of 63’s.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au